



(51) International Patent Classification:

A01N 45/00 (2006.01) *A61K 31/56* (2006.01)
A61K 31/50 (2006.01)

(21) International Application Number:

PCT/US2011/024174

(22) International Filing Date:

9 February 2011 (09.02.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/303,520 11 February 2010 (11.02.2010) US

(71) Applicant (for all designated States except US): **GLAXOSMITHKLINE LLC** [US/US]; One Franklin Plaza, 200 North 16th Street, Philadelphia, Pennsylvania 19102 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GAO, Daxin** [CN/CN]; c/o GlaxoSmithKline, R & D China Singapore Research Centre, 11 Biopolis Way, The Helios #06-03/04, Singapore, Commonwealth 138667 (CN). **HAN, Nianhe** [US/CN]; c/o GlaxoSmithKline, R & D China Singapore Research Centre, 11 Biopolis Way, The Helios #06-03/04, Singapore, Commonwealth 138667 (CN). **JIN, Zhimin** [CN/CN]; c/o GlaxoSmithKline, R & D China Singapore Research Centre, 11 Biopolis Way The Helios #06-03/04, Singapore, Commonwealth 138667 (CN). **NING, Fangxian** [CN/CN]; c/o GlaxoSmithKline, R & D China Singapore Research Centre, 11 Biopolis Way The Helios #06-03/04, Singapore, Com-

monwealth 138667 (CN). **TANG, Jun** [CN/US]; c/o GlaxoSmithKline, Global Patents, Five Moore Drive, P. O. Box 13398, Research Triangle Park, North Carolina 27709 (US). **WU, Yongyong** [CN/CN]; c/o GlaxoSmithKline, R & D China Singapore Research Centre, 11 Biopolis Way The Helios #06-03/04, Singapore, Commonwealth 138667 (CN). **YANG, Heping** [CN/CN]; c/o GlaxoSmithKline, R & D China Singapore Research Centre, 11 Biopolis Way The Helios #06-03/04, Singapore, Commonwealth 138667 (CN).


(74) Agents: **CARTER, Barbara J.** et al.; c/o GlaxoSmithKline, Global Patents Dept., Five Moore Drive, P. O. Box 13398, Research Triangle Park, North Carolina 27709 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: DERIVATIVES OF BETULIN



Formula I

(57) **Abstract:** The present invention relates to a compound characterized by Formula I or a pharmaceutically acceptable salt thereof, wherein R^1 , R^2 , R^3 , X, and Y are as described herein. Compounds of the present invention are useful for the treatment of HIV-1.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, **Published:**
GW, ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*